Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
NEOsphere Biotechnologies is accelerating drug discovery through high-throughput proteomics, enabling efficient screening of molecular glue libraries and systematic identification of clinically relevant degraders.
Defence Therapeutics’ proprietary Accum technology platform reduces the half-maximal inhibitory concentration (IC50) of antibody–drug conjugates up to fifty-fold by solving the endosome-entrapment problem.
The government-funded organization supports Korean biotech and pharma companies in more than 100 pipelines annually to discover, develop and test the most promising therapeutic candidates.
The clinical success of biologics is often hindered by a lack of safe, targeted delivery systems. SiVEC Biotechnologies aims to change this with its groundbreaking BactPac platform.
Transcenta is employing its unique, cutting-edge discovery technology to develop antibody-based therapies that address unmet medical needs in oncology, immunology and inflammation.
Bio-Sourcing is developing innovative solutions that combine cutting-edge gene-editing and nuclear-transfer technologies to up-scale the production of biopharmaceuticals while lowering carbon emissions and costs.
Hua Medicine is developing potentially disease-modifying therapeutics for type 2 diabetes, driven by mechanisms in the glucose homeostasis process. Having launched dorzagliatin in China in 2022, the company aims to transform diabetes treatment globally with its next generation glucokinase activator.
With its innovative VECTrans platform, Vect-Horus is enabling targeted drug delivery across the blood–brain barrier, potentially transforming the treatment of neurodegenerative disorders.
Nutcracker Therapeutics is driving down costs, accelerating speed of processing and improving scalability with an end-to-end, GMP-grade production process.
Harbour BioMed and Nona Biosciences have established a model for independent, synergistic activity to maximize their strengths, showing the possibilities for turning deep technology and global partnerships into sustainable growth.
Partex is using its platform driven by big data, AI and blockchain to identify overlooked pharma assets and slash the time and costs involved in bringing new therapies to patients.
CrossBridge Bio’s innovative approach to create stable, multi-loaded antibody–drug conjugates is set to generate a suite of first-in-class and best-in-class cancer therapies.
CorreGene’s first-in-class T-cell receptor-based T-cell engager drug, CRPA1A2, is ready to enter clinical trials. The technology platforms used to generate CRPA1A2 are supporting a rapidly expanding pipeline of TCEs for hard-to-treat cancers with high unmet clinical need.
PROVIREX is developing first-in-class advanced therapies that may offer the chance of a cure for people with life-threatening persistent viral infections.
